News | July 28, 2022
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
Subscribe To Our Newsletter & Stay Updated
